Pharma goes to the laundry: Public relations and the business of medical education

Hastings Center Report

Volumn 34, Issue 5, 2004, Pages 18-23

  Elliott, Carl ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; SERTRALINE;

CLINICAL TRIAL; COMMERCIAL PHENOMENA; CONTINUING EDUCATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; ETHICS; HUMAN; LAW SUIT; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL LITERATURE; PUBLIC RELATIONS; PUBLICATION; PULMONARY HYPERTENSION; REVIEW; VALVULAR HEART DISEASE; DRUG THERAPY; ECONOMICS; FORGERY; HEALTH CARE AND PUBLIC HEALTH; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT;

HEALTH CARE AND PUBLIC HEALTH;

DRUG INDUSTRY; DRUG THERAPY; EDUCATION, MEDICAL, CONTINUING; FRAUD; HUMANS; PERIODICALS; PUBLIC RELATIONS;

EID: 14644434333     PISSN: 00930334     EISSN: None     Source Type: Journal    
DOI: 10.2307/3527586     Document Type: Review

References (55)

1. N. Kendle, "Life Without a Label," Pharmaceutical Marketing, June 1, 2001.
2. A.S. Relman, "Separating Continuing Medical Education from Pharmaceutical Marketing," JAMA 285 (2001): 2009-2012.
3. "Drug Company Influence on Medical Education in USA," Lancet 356 (2000): 781.
4. S. Hensley, "Drug Firms Shown Classroom Door: Continuing-Ed Programs For Doctors Aim to Reduce Influence of Big Companies," Wall Street Journal, January 14, 2003.
5. M. Petersen, "Madison Ave. Has Growing Role In the Business of Drug Research," New York Times, November 22, 2002.
6. D. Hanners, "Documents Indicate Tobacco Industry Paid Scientists to Write to Editors," St. Paul Pioneer Press, August 5, 1998.
7. M. Petersen, "Court Papers Suggest Scale of Drug's Use," New York Times, May 30, 2003.
8. A. Flanagin et al., "Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals," JAMA 280 (1998): 222-24.
9. D. Healy and D. Cattell, "Interface between Authorship, Industry and Science in the Domain of Therapeutics," British Journal of Psychiatry 183 (2003): 22-27.
10. A. Barrett, "The Class Action That Wouldn't Quit: The Cost of Wyeth's Diet-Drug Disaster: $16.6 Billion. And the Claims Keep Coming," Business Week, May 24, 2004.
11. Morbidity and Mortality Weekly Report 46, no. 45, November 14, 1997.
12. The FDSA linked Redux, which was only on the market for a year, to 123 deaths when it was withdrawn in 1997. Pondimin was marketed for a longer period, Mundy estimates the total number of deaths to be close to 1,000. See David Willmon, "The New FDA," Los Angeles Times, Dec 20, 2000, and Alica Mundy, personal correspondence, August 11, 2004.
13. A. Mundy, Dispensing with the Truth (New York: St. Martin's Press, 2001), 159, 181-82.
14. Ibid., 9.
15. J. Brown, "The Poison Pill," Salon, May 16, 2001.
16. M. Kaufman and A. Julien, "Scientists Helped Industry to Push Diet Drug," Hartford Courant, April 10, 2000.
17. Mundy, Dispensing with the Truth, 41.
18. Ibid., 79-80.
19. J.E. Manson and G.A. Faich, "Pharmacotherapy for Obesity: Do the Benefits Outweigh the Risks?" NEJM 335 (1996): 659-60; M. Angell and J. Kassirer, "Editorials and Conflicts of Interest," NEJM 335 (1996): 1055-1056; Mundy, Dispensing with the Truth, 81, 121-25.
20. J.E. Manson and G.A. Faich, "Pharmacotherapy for Obesity: Do the Benefits Outweigh the Risks?" NEJM 335 (1996): 659-60; M. Angell and J. Kassirer, "Editorials and Conflicts of Interest," NEJM 335 (1996): 1055-1056; Mundy, Dispensing with the Truth, 81, 121-25.
21. J.E. Manson and G.A. Faich, "Pharmacotherapy for Obesity: Do the Benefits Outweigh the Risks?" NEJM 335 (1996): 659-60; M. Angell and J. Kassirer, "Editorials and Conflicts of Interest," NEJM 335 (1996): 1055-1056; Mundy, Dispensing with the Truth, 81, 121-25.
22. Kauffman and Julien, "Scientists Helped Industry to Push Diet Drug."
23. C. Ornstein, "Maker of Diet-Drug Combo Accused to Funding Journal Articles," Dallas Morning News, May 23, 1999.
24. Ibid.; see also Mundy, Dispensing with the Truth, 164.
25. Ibid.; see also Mundy, Dispensing with the Truth, 164.
26. Ibid., 115.
27. Ibid., 119.
28. Ibid., 122-23.
29. Ibid., 116-19.
30. S. Okie, "AMA Criticized for Letting Drug Firms Pay for Ethics Campaign," Washington Post, August 30, 2001.
31. A. Relman, "Defending Professional Independence: ACCME's Prposed New Guidelines for Commerical Support of CME," JAMA 289 (2003): 2418-2420.
32. See C. Medawar and A. Hardon, Medicines Out of Control? Antidepressants and the Conspiracy of Goodwill (Amsterdam: Transaction Publishers, 2004); and David Healy, Let Them Eat Prozac (New York: New York University Press, 2004).
33. See C. Medawar and A. Hardon, Medicines Out of Control? Antidepressants and the Conspiracy of Goodwill (Amsterdam: Transaction Publishers, 2004); and David Healy, Let Them Eat Prozac (New York: New York University Press, 2004).
34. J. Lenzer, "Pfizer Pleads Guilty but Drug Sales Continue to Soar," BMJ 328 (2004): 1217.
35. Petersen, "Madison Ave. Has Growing Role in Business of Drug Research."
36. T. Jackson, "Are You Being Duped? How Drug Companies Use Opinion Leaders," BMJ 322 (2001): 1312.
37. The Center for Science in the Public Interest maintains a searchable database on the financial ties of non-profit groups and scientists to corporate sources. It can be found at http://cspinet.org/integrity/nonprofits/.
38. Relman, "Separating Continuing Medical Education from Pharmaceutical Marketing."
39. B. Als-Nielsen et al., "Association of Funding and Conclusions in Randomized Drug Trials," JAMA 290 (2003): 921-28; R.A. Davidson, "Source of Funding and Outcome of Clinical Trials," Journal of General Internal Medicine 1, no. 3 (1986): 155-58.
40. B. Als-Nielsen et al., "Association of Funding and Conclusions in Randomized Drug Trials," JAMA 290 (2003): 921-28; R.A. Davidson, "Source of Funding and Outcome of Clinical Trials," Journal of General Internal Medicine 1, no. 3 (1986): 155-58.
41. See A. Wazana, "Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?" JAMA 283 (2000): 373-80; M.M. Chren and C.S. Landefeld, "Physicians' Behavior and Their Interaction with Drug Companies," JAMA 271 (1994): 684-89; J.P. Orlowski and L. Wateska, "The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns," Chest 102 (1992): 270-73.
42. See A. Wazana, "Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?" JAMA 283 (2000): 373-80; M.M. Chren and C.S. Landefeld, "Physicians' Behavior and Their Interaction with Drug Companies," JAMA 271 (1994): 684-89; J.P. Orlowski and L. Wateska, "The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns," Chest 102 (1992): 270-73.
43. See A. Wazana, "Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?" JAMA 283 (2000): 373-80; M.M. Chren and C.S. Landefeld, "Physicians' Behavior and Their Interaction with Drug Companies," JAMA 271 (1994): 684-89; J.P. Orlowski and L. Wateska, "The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns," Chest 102 (1992): 270-73.
44. S. Krimsky and L. Rothenberg, "Conflict of Interest Policies in Science and Medical Journals: Editorial Practices and Author Disclosures," Science and Engineering Ethics 7, no. 2 (2001): 205-17.
45. T. Brennan, "Buying Editorials," NEJM 331 (1994): 673-75.
46. B. Tansey, "Huge Penalty in Drug Fraud; Pfizer Settles Felony Case in Neurontin Off-label Promotion," San Francisco Chronicle, May 14, 2004. For information about the Pfizer Foundation Hall for Humanism in Medicine, see R. Moynihan, "The Making of a Disease: Female Sexual Dysfunction," BMJ 326 (2003): 45-47. Information about Pfizer's New York University School of Medicine Master Scholars Program is available at http://tutorialspub.med.nyu. edu/Content/MSP/ MSPBrochure.pdf. An announcement of the Pfizer Lecturer in Medical Humanities is reported in the Journal of Medical Ethics: Medical Humanities 27 (2001): 69. For the Nigerian Trovan trials, see A. Raufu, "Nigerians in Drug Trial Take Their Case to U.S. Court," BMJ 326 (2003): 899. The University of Pennsylvania Center for Bioethics discloses its funding sources at http://www.bioethics.upenn.edu/resources/. For the Pfizer-funded article on conflict of interest, see D. Katz, A. Caplan, and J. Merz, "All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving," American Journal of Bioethics 3, no. 3 (2003): 39-46. On the director's Pfizer consultancy, see L. Weeks, "Viagra Debate Vigorous; Drug Sparks Questions of Sexual Politics," Washington Post, April 26, 1998.
47. B. Tansey, "Huge Penalty in Drug Fraud; Pfizer Settles Felony Case in Neurontin Off-label Promotion," San Francisco Chronicle, May 14, 2004. For information about the Pfizer Foundation Hall for Humanism in Medicine, see R. Moynihan, "The Making of a Disease: Female Sexual Dysfunction," BMJ 326 (2003): 45-47. Information about Pfizer's New York University School of Medicine Master Scholars Program is available at http://tutorialspub.med.nyu. edu/Content/MSP/ MSPBrochure.pdf. An announcement of the Pfizer Lecturer in Medical Humanities is reported in the Journal of Medical Ethics: Medical Humanities 27 (2001): 69. For the Nigerian Trovan trials, see A. Raufu, "Nigerians in Drug Trial Take Their Case to U.S. Court," BMJ 326 (2003): 899. The University of Pennsylvania Center for Bioethics discloses its funding sources at http://www.bioethics.upenn.edu/resources/. For the Pfizer-funded article on conflict of interest, see D. Katz, A. Caplan, and J. Merz, "All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving," American Journal of Bioethics 3, no. 3 (2003): 39-46. On the director's Pfizer consultancy, see L. Weeks, "Viagra Debate Vigorous; Drug Sparks Questions of Sexual Politics," Washington Post, April 26, 1998.
48. B. Tansey, "Huge Penalty in Drug Fraud; Pfizer Settles Felony Case in Neurontin Off-label Promotion," San Francisco Chronicle, May 14, 2004. For information about the Pfizer Foundation Hall for Humanism in Medicine, see R. Moynihan, "The Making of a Disease: Female Sexual Dysfunction," BMJ 326 (2003): 45-47. Information about Pfizer's New York University School of Medicine Master Scholars Program is available at http://tutorialspub.med.nyu. edu/Content/MSP/ MSPBrochure.pdf. An announcement of the Pfizer Lecturer in Medical Humanities is reported in the Journal of Medical Ethics: Medical Humanities 27 (2001): 69. For the Nigerian Trovan trials, see A. Raufu, "Nigerians in Drug Trial Take Their Case to U.S. Court," BMJ 326 (2003): 899. The University of Pennsylvania Center for Bioethics discloses its funding sources at http://www.bioethics.upenn.edu/resources/. For the Pfizer-funded article on conflict of interest, see D. Katz, A. Caplan, and J. Merz, "All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving," American Journal of Bioethics 3, no. 3 (2003): 39-46. On the director's Pfizer consultancy, see L. Weeks, "Viagra Debate Vigorous; Drug Sparks Questions of Sexual Politics," Washington Post, April 26, 1998.
49. B. Tansey, "Huge Penalty in Drug Fraud; Pfizer Settles Felony Case in Neurontin Off-label Promotion," San Francisco Chronicle, May 14, 2004. For information about the Pfizer Foundation Hall for Humanism in Medicine, see R. Moynihan, "The Making of a Disease: Female Sexual Dysfunction," BMJ 326 (2003): 45-47. Information about Pfizer's New York University School of Medicine Master Scholars Program is available at http://tutorialspub.med.nyu. edu/Content/MSP/ MSPBrochure.pdf. An announcement of the Pfizer Lecturer in Medical Humanities is reported in the Journal of Medical Ethics: Medical Humanities 27 (2001): 69. For the Nigerian Trovan trials, see A. Raufu, "Nigerians in Drug Trial Take Their Case to U.S. Court," BMJ 326 (2003): 899. The University of Pennsylvania Center for Bioethics discloses its funding sources at http://www.bioethics.upenn.edu/resources/. For the Pfizer-funded article on conflict of interest, see D. Katz, A. Caplan, and J. Merz, "All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving," American Journal of Bioethics 3, no. 3 (2003): 39-46. On the director's Pfizer consultancy, see L. Weeks, "Viagra Debate Vigorous; Drug Sparks Questions of Sexual Politics," Washington Post, April 26, 1998.
50. B. Tansey, "Huge Penalty in Drug Fraud; Pfizer Settles Felony Case in Neurontin Off-label Promotion," San Francisco Chronicle, May 14, 2004. For information about the Pfizer Foundation Hall for Humanism in Medicine, see R. Moynihan, "The Making of a Disease: Female Sexual Dysfunction," BMJ 326 (2003): 45-47. Information about Pfizer's New York University School of Medicine Master Scholars Program is available at http://tutorialspub.med.nyu. edu/Content/MSP/ MSPBrochure.pdf. An announcement of the Pfizer Lecturer in Medical Humanities is reported in the Journal of Medical Ethics: Medical Humanities 27 (2001): 69. For the Nigerian Trovan trials, see A. Raufu, "Nigerians in Drug Trial Take Their Case to U.S. Court," BMJ 326 (2003): 899. The University of Pennsylvania Center for Bioethics discloses its funding sources at http://www.bioethics.upenn.edu/resources/. For the Pfizer-funded article on conflict of interest, see D. Katz, A. Caplan, and J. Merz, "All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving," American Journal of Bioethics 3, no. 3 (2003): 39-46. On the director's Pfizer consultancy, see L. Weeks, "Viagra Debate Vigorous; Drug Sparks Questions of Sexual Politics," Washington Post, April 26, 1998.
51. B. Tansey, "Huge Penalty in Drug Fraud; Pfizer Settles Felony Case in Neurontin Off-label Promotion," San Francisco Chronicle, May 14, 2004. For information about the Pfizer Foundation Hall for Humanism in Medicine, see R. Moynihan, "The Making of a Disease: Female Sexual Dysfunction," BMJ 326 (2003): 45-47. Information about Pfizer's New York University School of Medicine Master Scholars Program is available at http://tutorialspub.med.nyu. edu/Content/MSP/ MSPBrochure.pdf. An announcement of the Pfizer Lecturer in Medical Humanities is reported in the Journal of Medical Ethics: Medical Humanities 27 (2001): 69. For the Nigerian Trovan trials, see A. Raufu, "Nigerians in Drug Trial Take Their Case to U.S. Court," BMJ 326 (2003): 899. The University of Pennsylvania Center for Bioethics discloses its funding sources at http://www.bioethics.upenn.edu/resources/. For the Pfizer-funded article on conflict of interest, see D. Katz, A. Caplan, and J. Merz, "All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving," American Journal of Bioethics 3, no. 3 (2003): 39-46. On the director's Pfizer consultancy, see L. Weeks, "Viagra Debate Vigorous; Drug Sparks Questions of Sexual Politics," Washington Post, April 26, 1998.
52. The participants in the 2001 Confernce on Ethical Aspects of Research in Developing Countries, "Moral Standards for Research in Developing Countries: From 'Reasonable Availabitlity' to 'Fair Benefits,'" Hastings Center Report 34, no. 3 (2004):17-27.
53. T. Donaldson, "The Business Ethics of Bioethics Consulting," Hastings Center Report 31, no. 2 (2001): 13.
54. Petersen, "Madison Ave. Has Growing Role In the Business of Drug Research." See also the revealing account of a former drug representative: M.J. Oldani, "Tales from the 'Script': An Insider/Outside View of Pharmaceutical Sales Practices," Krober Anthropological Society 87 (2002): 146-76.
55. Petersen, "Madison Ave. Has Growing Role In the Business of Drug Research." See also the revealing account of a former drug representative: M.J. Oldani, "Tales from the 'Script': An Insider/Outside View of Pharmaceutical Sales Practices," Krober Anthropological Society 87 (2002): 146-76.